B-cell Inhibitors Market for Non-Oncology Diseases, 2026-2035 Industry Trends and Global Forecasts - Growing Prevalence of Autoimmune Disorders and Hematologic Cancers Drives Rapid Advancement
Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "B-cell Inhibitors Market for Non-Oncology Diseases: Industry Trends and Global Forecasts, Till 2035 - Distribution by Stage of Development, Indication and Key Geographies" report has been added to ResearchAndMarkets.com's offering.
The global B-cell inhibitors market for non-oncology diseases is estimated to grow from USD 21.2 billion in the current year to USD 51.5 billion by 2035, at a CAGR of 9.30% during the forecast period, till 2035.
B-cell inhibitors are essential for regulating immune responses and are used in treating autoimmune diseases and B-cell malignancies. Significantly, B cell inhibitors function by targeting B cells through various mechanisms. Monoclonal antibodies that target B-cell surface markers such as CD20 and CD19 interfere with survival signals, whereas small molecule inhibitors, such as Bruton's tyrosine kinase disrupt B-cell receptor signaling pathways, thus hindering B-cell activation, proliferation, and survival.
These treatments have demonstrated wide-ranging effectiveness in addressing issues such as lymphomas, chronic lymphocytic leukemia, multiple sclerosis, and lupus. Currently, more than 400 B-cell inhibitors are at various phases of clinical testing for non-oncology diseases. Further, the industry has witnessed notable investments and strategic partnerships due to its ability to overcome current production constraints and enhance therapeutic results. Consequently, such developments highlight the increasing focus towards tackling unfulfilled medical requirements. B-cell inhibitors are expected to see significant growth, positioning them as critical enablers of the next generation of genetic medicines.
The market for B-cell inhibitors is expanding due to the increasing occurrence of autoimmune diseases, such as rheumatoid arthritis and lupus, as well as blood cancers, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. Additionally, the rising need for targeted immunomodulatory therapies that have fewer side effects than conventional treatments is driving investment and innovation in this field.
B -CELL INHIBITORS MARKET FOR NON-ONCOLOGY DISEASES: KEY SEGMENTS
Marketed Sub-Segment Holds the Largest Market Share in the B-cell Inhibitors Market for Non-oncology Diseases
In terms of stage of development, the B-cell inhibitors market for non-oncology diseases is distributed across phase II, phase III and marketed. In the current year, the marketed sub-segment occupies the highest market share (over 80%), owing to the strong presence of B-cell Inhibitors, such as rituximab and ibrutinib.
These inhibitors are known to cater to multiple indications, thus leading to expansion in their market reach. The market for B-cell Inhibitors in phase III is likely to witness a significant growth rate (CAGR) of 43% during the forecast period. This is because of the rising prevalence of autoimmune disorders across different countries.
Multiple Sclerosis Sub-Segment Holds the Largest B-cell Inhibitors Market for Non-oncology Diseases Share
In terms of indication, the B-cell inhibitors market for non-oncology diseases is distributed across ANCA, Graves' disease, hidradenitis suppurativa, immune thrombocytopenia, immunoglobulin nephropathy, membranous nephropathy, multiple sclerosis, myasthenia gravis, neuromyelitis optica, rheumatoid arthritis, sickle cell anemia, systemic lupus erythematosus, warm autoimmune hemolytic anemia. In the current year, the multiple sclerosis sub-segment holds the largest market share.
This is due to the fact that multiple inhibitors have received approval for this indication across different regions. Some of these approved drugs include alemtuzumab, baricitinib, belimumab and ocrelizumab. Further, we anticipate the market to witness a substantial increase in the share of immunoglobulin nephropathy sub-segment, growing at a CAGR of 34% during the forecast period. This is because several B-cell Inhibitors are currently in the later stages of development and are likely to receive approval in the coming year.
North America Constitutes the Largest B-cell Inhibitors Market for Non-oncology Diseases Share
According to the B-cell inhibitors market for non-oncology diseases share analysis, North America is likely to capture the majority (~75%) of the B-cell Inhibitors Market for Non-oncology Diseases share in the current year.
This is because North America has developed advanced healthcare infrastructure that allows developers to carry out extensive clinical trials to collect data for regulatory approval. It is worth highlighting that the market in China is likely to have higher B-cell Inhibitors Market for Non-oncology Diseases growth rate (15%). This is due to the rapidly growing patient population, the rising incidence of various indications in this country.
B-CELL INHIBITORS MARKET FOR NON-ONCOLOGY DISEASES: KEY INSIGHTS
The report delves into the current state of the B-cell inhibitors market for non-oncology diseases and identifies potential growth opportunities within industry. Some key findings from the report include:
Players in the B-cell Inhibitors Market for Non-oncology Diseases
REASONS TO BUY THIS REPORT
KEY QUESTIONS ANSWERED IN THIS REPORT
ADDITIONAL BENEFITS
COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/6y8l0v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.